Beth LeBow
Lawyers
Filters
Revance Therapeutics, Inc. $110 Million Common Stock Offering
Davis Polk advised the joint lead book-running managers and representatives of the several underwriters in connection with a $110.5 million SEC-registered common stock offering by…
Davis Polk Advises CrowdStrike Holdings, Inc. on Its $703.8 Million Initial Public Offering
Davis Polk advised CrowdStrike Holdings, Inc. on its SEC-registered initial public offering of 20,700,000 shares of Class A common stock for an aggregate price to the public of…
IDEAYA Biosciences, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of IDEAYA Biosciences, Inc. at $10.00 per share (which includes the…
NGM Biopharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…
Revance Therapeutics, Inc. $115 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $115 million SEC-registered common stock offering by Revance…
Taiwan Liposome Company, Ltd. Initial Public Offering
Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public offering by Taiwan Liposome Company, Ltd. of American Depositary…
Revance Therapeutics, Inc. $190 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock offering of 6,139,515 shares of common stock of Revance Therapeutics,…